Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Alterity Therapeutics
September 28, 2021
Biohaven’s latest failure is far from systemic
August 03, 2016
Therapy focus – One step forward but two steps back in Huntington’s
January 08, 2015
Buoyant small pharma market hides some big losers
October 06, 2014
Acquisitions help define performance of mid and small cap stocks
July 03, 2014
Market wobble fails to derail mid and small-caps
February 21, 2014
Glimmers of hope in Huntington's must not be overstated
April 11, 2013
Therapeutic focus – Two steps back for Huntington’s disease
April 04, 2011
Pharmasset the stand out small cap performer in first quarter
March 29, 2011
Interest in Australian pharma sector continues to grow
February 04, 2010
Therapeutic focus - Huntexil at spout of dry Huntington's disease pipeline
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
January 17, 2023
JP Morgan Healthcare Conference 2023
January 12, 2023
Evaluate Vantage 2023 Preview Infographic
Editor's Picks
February 01, 2023
Novartis trims its pipeline
January 30, 2023
The end of the Humira era
January 05, 2023
The biggest-selling drugs of 2023
January 31, 2023
Astrazeneca gets personal
February 06, 2023
The slow death of the medtech Spac deal